Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925).
Details
Serval ID
serval:BIB_2F30861B4E28
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925).
Journal
Acta Oncologica
Working group(s)
EORTC Radiation Oncology & Breast Cancer Groups
Contributor(s)
Poortmans PH., Van Den Bogaert W., Kirkove C., Budach VG., Maingon P., Carla Valli M., Immerzeel JJ., Warlam-Rodenhuis C., Le Pechoux C., Bamberg M., Van Tienhoven G., Glanzmann C., Lutolf UM., Fourquet A., Kuten A., Quetin P., Baeza R., David M., Jobsen J., Sunyach MP., Bartelink H., Russell N., Van Leeuwenhoekziekenhuis A., Mirimanoff RO., Bolla M., Beauduin M., Pfeffer R., Lagrange JL., Dilhuydy JM., Chenal , Benchalal M., Huget P., Courdi A., Bosset JF., Kobierska A., Senkus-Konefka E., Kurtz J., Balmer-Majno S., Koswig S., Krebs H., Bongartz R., Struikmans H., Amalric F., Dolsma WV., Jager JJ., Stellamans K., Guenzi M., Stuschke M., Villa S., Boladeras A., Basic H., Badinez L., Silva I., Muller HM., Strnad V.
ISSN
1651-226X (Electronic)
ISSN-L
0284-186X
Publication state
Published
Issued date
2010
Volume
49
Number
1
Pages
24-34
Language
english
Notes
Publication types: Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Abstract
INTRODUCTION: The EORTC 22922/10925 trial investigated the potential survival benefit and toxicity of elective irradiation of the internal mammary and medial supraclavicular (IM-MS) nodes Accrual completed in January 2004 and first results are expected in 2012. We present the toxicity reported until year 3 after treatment.
PATIENTS AND METHODS: At each visit, toxicity was reported but severity was not graded routinely. Toxicity rates and performance status (PS) changes at three years were compared by chi(2) tests and logistic regression models in all the 3,866 of 4,004 patients eligible to the trial who received the allocated treatment.
RESULTS: Only lung (fibrosis; dyspnoea; pneumonitis; any lung toxicities) (4.3% vs. 1.3%; p < 0.0001) but not cardiac toxicity (0.3% vs. 0.4%; p = 0.55) significantly increased with IM-MS treatment. No significant worsening of the PS was observed (p = 0.79), suggesting that treatment-related toxicity does not impair patient's daily activities.
CONCLUSIONS: IM-MS irradiation seems well tolerated and does not significantly impair WHO PS at three years. A follow-up period of at least 10 years is needed to determine whether cardiac toxicity is increased after radiotherapy.
PATIENTS AND METHODS: At each visit, toxicity was reported but severity was not graded routinely. Toxicity rates and performance status (PS) changes at three years were compared by chi(2) tests and logistic regression models in all the 3,866 of 4,004 patients eligible to the trial who received the allocated treatment.
RESULTS: Only lung (fibrosis; dyspnoea; pneumonitis; any lung toxicities) (4.3% vs. 1.3%; p < 0.0001) but not cardiac toxicity (0.3% vs. 0.4%; p = 0.55) significantly increased with IM-MS treatment. No significant worsening of the PS was observed (p = 0.79), suggesting that treatment-related toxicity does not impair patient's daily activities.
CONCLUSIONS: IM-MS irradiation seems well tolerated and does not significantly impair WHO PS at three years. A follow-up period of at least 10 years is needed to determine whether cardiac toxicity is increased after radiotherapy.
Keywords
Adult, Aged, Breast Neoplasms/pathology, Breast Neoplasms/radiotherapy, Chemotherapy, Adjuvant, Combined Modality Therapy, Female, Heart/radiation effects, Humans, Lymphatic Metastasis/radiotherapy, Mastectomy, Middle Aged, Neoplasm Staging, Pulmonary Fibrosis/etiology, Radiotherapy/adverse effects, Severity of Illness Index
Pubmed
Web of science
Create date
16/02/2010 11:37
Last modification date
20/08/2019 13:13
Usage data
